Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Labrie

Showing results (661-670 of 723) with videos related to

Pageof 73
Sort By:
The Prostate|August 29, 2000
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerB Candas, L Cusan, J L Gomez, et al.
Structure (London, England : 1993)|May 15, 1995
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolutionD Ghosh, V Z Pletnev, D W Zhu, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trialF Labrie, A Dupont, L Cusan, et al.
Biochemistry|March 7, 1995
Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSDE Rhéaume, R Sanchez, F Mébarki, et al.
Urology|March 1, 1997
Neoadjuvant hormonal therapy: the Canadian experienceF Labrie, L Cusan, J L Gomez, et al.
The American Journal of Surgical Pathology|January 1, 1996
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized studyL Vailancourt, B Ttu, Y Fradet, et al.
Advances in Experimental Medicine and Biology|January 1, 1979
Inhibitory effects of treatment with LHRH or its agonists on ovarian receptor levels and functionF Labrie, C Auclair, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigenF Labrie, A Dupont, R Suburu, et al.
JAMA|February 15, 1995
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screeningD Shattuck-Eidens, M McClure, J Simard, et al.
Journal of Steroid Biochemistry|January 1, 1988
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choiceF Labrie, A Dupont, L Cusan, et al.
Pageof 73

Showing results (661-670 of 723) with videos related to

Sort By:
Pageof 73
The Prostate|August 29, 2000
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerB Candas, L Cusan, J L Gomez, et al.
Structure (London, England : 1993)|May 15, 1995
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolutionD Ghosh, V Z Pletnev, D W Zhu, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trialF Labrie, A Dupont, L Cusan, et al.
Biochemistry|March 7, 1995
Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSDE Rhéaume, R Sanchez, F Mébarki, et al.
Urology|March 1, 1997
Neoadjuvant hormonal therapy: the Canadian experienceF Labrie, L Cusan, J L Gomez, et al.
The American Journal of Surgical Pathology|January 1, 1996
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized studyL Vailancourt, B Ttu, Y Fradet, et al.
Advances in Experimental Medicine and Biology|January 1, 1979
Inhibitory effects of treatment with LHRH or its agonists on ovarian receptor levels and functionF Labrie, C Auclair, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigenF Labrie, A Dupont, R Suburu, et al.
JAMA|February 15, 1995
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screeningD Shattuck-Eidens, M McClure, J Simard, et al.
Journal of Steroid Biochemistry|January 1, 1988
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choiceF Labrie, A Dupont, L Cusan, et al.
Pageof 73